Seeking Alpha · 4 Oct 2026positive
Pyxis Oncology's main value driver, the oncology drug candidate MICVO, has shown promising early data but still requires a safe and effective dose. A recent capital raise strengthens the company's near-term financing and should support reaching important clinical milestones with MICVO.
Why it matters — PYXS watchers would care because the strengthened runway helps fund progress on MICVO, the company's key clinical value driver.
GlobeNewsWire · 2 Oct 2026neutral
Pyxis Oncology closed its previously announced registered public offering on October 1, 2026, generating approximately $110.0 million in upfront gross proceeds before underwriting discounts, commissions, and other expenses. The offering comprised 36,047,919 shares of common stock at $2.90 per share and pre-funded warrants for 1,883,121 shares at $2.899 each, with common warrants for an aggregate of 49,310,352 shares.
Why it matters — The closing of this up to $282.6 million public offering provides Pyxis Oncology with additional capital to support its clinical-stage development of next-generation cancer therapeutics.
GlobeNewsWire · 30 Sept 2026neutral
Pyxis Oncology priced a registered public offering of 36,047,919 shares of common stock, or pre-funded warrants in lieu of stock to certain investors, along with accompanying common warrants, expecting gross proceeds of approximately $110 million, with up to $172.6 million more if all warrants are exercised.
Why it matters — PYXS watchers would care because the offering provides the clinical-stage company with additional capital to fund its next-generation cancer therapeutics programs.
GlobeNewsWire · 29 Sept 2026negative
Pyxis Oncology announced that it has commenced a registered public offering of shares of its common stock, or in lieu of common stock to certain investors, pre-funded warrants to purchase common stock. Each share and pre-funded warrant will be sold together with a common warrant to purchase one share of common stock.
Why it matters — A public offering typically dilutes existing shareholders, so PYXS watchers would want to monitor the announcement's potential impact on the company's share count and capital structure.
Seeking Alpha · 10 Sept 2026neutral
Pyxis Oncology discussed its MICVO monotherapy Phase I clinical data in head and neck squamous cell carcinoma during a presentation transcript. The item shares this discussion as published by Seeking Alpha.
Why it matters — PYXS watchers would follow this as an update on the company's early-stage clinical program for MICVO in HNSCC.
